Skip to main navigation Skip to search Skip to main content

Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro

  • Hsien Ming Wu*
  • , Liang Hsuan Chen
  • , Andrew V. Schally
  • , Hong Yuan Huang
  • , Yung Kuei Soong
  • , Peter C.K. Leung
  • , Hsin Shih Wang
  • *Corresponding author for this work
  • Chang Gung University
  • University of Miami
  • University of British Columbia

Research output: Contribution to journalJournal Article peer-review

4 Scopus citations

Abstract

Endometrial stromal cells remodeling is critical during human pregnancy. Growth hormone-releasing hormone and its functional receptor have been shown to be expressed in gynecological cancer cells and eutopic endometrial stromal cells. Recent studies have demonstrated the potential clinical uses of antagonists of growth hormone-releasing hormone as effective antitumor agents because of its directly antagonistic effect on the locally produced growth hormone-releasing hormone in gynecological tumors. However, the impact of growth hormone-releasing hormone antagonists on normal endometrial stromal cell growth remained to be elucidated. The aim of this study was to investigate the effect of a growth hormone-releasing hormone antagonist (JMR-132) on cell proliferation and apoptosis of human decidual stromal cells and the underlying molecular mechanisms. Our results showed that growth hormone-releasing hormone and the splice variant 1 of growth hormone-releasing hormone receptor are expressed in human decidual stromal cells isolated from the decidual tissues of early pregnant women receiving surgical abortion. In addition, treatment of stroma cells with JMR-132 induced cell apoptosis with increasing cleaved caspase-3 and caspase-9 activities and decrease cell viability in a time- and dose-dependent manner. Using a dual inhibition approach (pharmacological inhibitors and siRNA-mediated knockdown), we showed that JMR-132-induced activation of apoptotic signals are mediated by the activation of ERK1/2 and JNK signaling pathways and the subsequent upregulation of GADD45alpha. Taken together, JMR-132 suppresses cell survival of decidual stromal cells by inducing apoptosis through the activation of ERK1/2- and JNK-mediated upregulation of GADD45alpha in human endometrial stromal cells. Our findings provide new insights into the potential impact of growth hormone-releasing hormone antagonist on the decidual programming in humans.

Original languageEnglish
Pages (from-to)145-154
Number of pages10
JournalBiology of Reproduction
Volume106
Issue number1
DOIs
StatePublished - 01 01 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • ERK1/2
  • GADD45α
  • GHRH antagonist
  • JNK
  • apoptosis

Fingerprint

Dive into the research topics of 'Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro'. Together they form a unique fingerprint.

Cite this